Ivabradine

Heart failure and beyond

Rahul Chaudhary, Jalaj Garg, Parasuram Krishnamoorthy, Neeraj Shah, Gregg Lanier, Mathew W. Martinez, Ronald Freudenberger

Research output: Contribution to journalArticle

Abstract

Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current (If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative inotropic effect. Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure. This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths. Additionally, ivabradine has been associated with reduced cardiac remodeling, reduced heart rate variability, improvement in exercise tolerance, improved heart failure class of New York Heart Association, and better quality of life. It has also been tried in other conditions, such as inappropriate sinus tachycardia and cardiogenic shock, and is currently in phase II trial for patients with newly diagnosed multiple organ dysfunction syndrome.

Original languageEnglish (US)
Pages (from-to)335-343
Number of pages9
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume21
Issue number4
DOIs
StatePublished - Jan 1 2016

Fingerprint

ivabradine
Heart Failure
Heart Rate
Sinus Tachycardia
Systolic Heart Failure
Sinoatrial Node
Exercise Tolerance
Cardiogenic Shock
Multiple Organ Failure
United States Food and Drug Administration
Hospitalization
Quality of Life

Keywords

  • Funny current
  • HCN
  • Heart failure
  • Ivabradine
  • SHIFT
  • SIGNIFY

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Chaudhary, R., Garg, J., Krishnamoorthy, P., Shah, N., Lanier, G., Martinez, M. W., & Freudenberger, R. (2016). Ivabradine: Heart failure and beyond. Journal of Cardiovascular Pharmacology and Therapeutics, 21(4), 335-343. https://doi.org/10.1177/1074248415624157

Ivabradine : Heart failure and beyond. / Chaudhary, Rahul; Garg, Jalaj; Krishnamoorthy, Parasuram; Shah, Neeraj; Lanier, Gregg; Martinez, Mathew W.; Freudenberger, Ronald.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 21, No. 4, 01.01.2016, p. 335-343.

Research output: Contribution to journalArticle

Chaudhary, R, Garg, J, Krishnamoorthy, P, Shah, N, Lanier, G, Martinez, MW & Freudenberger, R 2016, 'Ivabradine: Heart failure and beyond', Journal of Cardiovascular Pharmacology and Therapeutics, vol. 21, no. 4, pp. 335-343. https://doi.org/10.1177/1074248415624157
Chaudhary R, Garg J, Krishnamoorthy P, Shah N, Lanier G, Martinez MW et al. Ivabradine: Heart failure and beyond. Journal of Cardiovascular Pharmacology and Therapeutics. 2016 Jan 1;21(4):335-343. https://doi.org/10.1177/1074248415624157
Chaudhary, Rahul ; Garg, Jalaj ; Krishnamoorthy, Parasuram ; Shah, Neeraj ; Lanier, Gregg ; Martinez, Mathew W. ; Freudenberger, Ronald. / Ivabradine : Heart failure and beyond. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2016 ; Vol. 21, No. 4. pp. 335-343.
@article{91c41bb10b934ce2bd76ac467b565e08,
title = "Ivabradine: Heart failure and beyond",
abstract = "Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current (If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative inotropic effect. Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure. This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths. Additionally, ivabradine has been associated with reduced cardiac remodeling, reduced heart rate variability, improvement in exercise tolerance, improved heart failure class of New York Heart Association, and better quality of life. It has also been tried in other conditions, such as inappropriate sinus tachycardia and cardiogenic shock, and is currently in phase II trial for patients with newly diagnosed multiple organ dysfunction syndrome.",
keywords = "Funny current, HCN, Heart failure, Ivabradine, SHIFT, SIGNIFY",
author = "Rahul Chaudhary and Jalaj Garg and Parasuram Krishnamoorthy and Neeraj Shah and Gregg Lanier and Martinez, {Mathew W.} and Ronald Freudenberger",
year = "2016",
month = "1",
day = "1",
doi = "10.1177/1074248415624157",
language = "English (US)",
volume = "21",
pages = "335--343",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Ivabradine

T2 - Heart failure and beyond

AU - Chaudhary, Rahul

AU - Garg, Jalaj

AU - Krishnamoorthy, Parasuram

AU - Shah, Neeraj

AU - Lanier, Gregg

AU - Martinez, Mathew W.

AU - Freudenberger, Ronald

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current (If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative inotropic effect. Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure. This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths. Additionally, ivabradine has been associated with reduced cardiac remodeling, reduced heart rate variability, improvement in exercise tolerance, improved heart failure class of New York Heart Association, and better quality of life. It has also been tried in other conditions, such as inappropriate sinus tachycardia and cardiogenic shock, and is currently in phase II trial for patients with newly diagnosed multiple organ dysfunction syndrome.

AB - Heart failure affects over 5 million people in the United States and carries a high rate of mortality. Ivabradine, a new agent has been added to the current medical options for managing heart failure. It is a selective funny current (If) inhibitor in sinoatrial node and slows its firing rate, prolonging diastolic depolarization without a negative inotropic effect. Ivabradine was only recently approved by Food and Drug administration after the results of Systolic Heart Failure Treatment with the If Inhibitor Ivabradine (SHIFT) trial, for a reduction in rehospitalizations from chronic heart failure. This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths. Additionally, ivabradine has been associated with reduced cardiac remodeling, reduced heart rate variability, improvement in exercise tolerance, improved heart failure class of New York Heart Association, and better quality of life. It has also been tried in other conditions, such as inappropriate sinus tachycardia and cardiogenic shock, and is currently in phase II trial for patients with newly diagnosed multiple organ dysfunction syndrome.

KW - Funny current

KW - HCN

KW - Heart failure

KW - Ivabradine

KW - SHIFT

KW - SIGNIFY

UR - http://www.scopus.com/inward/record.url?scp=84978872856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978872856&partnerID=8YFLogxK

U2 - 10.1177/1074248415624157

DO - 10.1177/1074248415624157

M3 - Article

VL - 21

SP - 335

EP - 343

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 4

ER -